Annals of Surgical Oncology

, Volume 14, Issue 9, pp 2550–2558 | Cite as

Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity

  • Shigeki Kusamura
  • Dario Baratti
  • Rami Younan
  • Barbara Laterza
  • Grazia Daniela Oliva
  • Pasqualina Costanzo
  • Myriam Favaro
  • Cecilia Gavazzi
  • Federica Grosso
  • Marcello Deraco
Gastrointestinal Oncology

Abstract

Introduction

The purpose of this study was to analyze the postoperative systemic toxicity and procedure-related mortality (PRM) of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal surface malignancies (PSMs).

Patients and methods

A total of 242 (84 males/158 females) patients with PSM underwent 247 consecutive procedures. The mean age was 52 years (range 22–79). CRS was performed using peritonectomy procedures. The HIPEC technique through the closed abdomen was conducted with cisplatin (CDDP 25 mg/m2/l of perfusate)+mitomycin C (MMC 3.3 mg/m2/l perfusate) or CDDP (43 mg/l perfusate)+doxorubicin (Dx 15.25 mg/l perfusate) at 42.5°C. These dosages were reduced by 30% when the patient had received systemic chemotherapy before the CRS+HIPEC. Systemic toxicities were graded according to the NCI CTCAE v3 criteria.

Results

G3-5 systemic toxicity rate was 11.7 % and adverse events were bone marrow suppression, 13; nephrotoxicity, 14; neutropenic infection, 2 and pulmonary toxicity, 1. Independent risk factors for G3-5 systemic toxicity after multivariate analysis were a dose of CDDP for HIPEC of 240 mg or more (OR 2.78, CI 95% 1.20–6.45) and CDDP+Dx schedule for HIPEC (OR 2.36, CI 95% 1.02–5.45). PRM was 1.2%.

Conclusions

CRS+HIPEC presented acceptable systemic toxicity and PRM rates. Independent risk factors for systemic toxicity were the CDDP+Dx schedule and CDDP dose for HIPEC.

Keywords

Peritonectomy Hyperthermic Intraperitoneal Chemotherapy Toxicity 

Notes

Acknowledgments

Supported in part by grants from the AIRC (Associazione Italiana Ricerca sul Cancro).

References

  1. 1.
    Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, Kusamura S. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11(4):393–398PubMedCrossRefGoogle Scholar
  2. 2.
    Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, Kusamura S. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003; 83:147–153PubMedCrossRefGoogle Scholar
  3. 3.
    Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, Kim SJ, Lee JM. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004; 94:325–332PubMedCrossRefGoogle Scholar
  4. 4.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22:3284–3292PubMedCrossRefGoogle Scholar
  5. 5.
    Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737–3743PubMedCrossRefGoogle Scholar
  6. 6.
    http://www.peritonealworkshop2006.com. Last access February 2007Google Scholar
  7. 7.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221:29–42PubMedCrossRefGoogle Scholar
  8. 8.
    Sugarbaker PH. Laser-mode electrosurgery. Cancer Treat Res 1996; 82:375–385PubMedGoogle Scholar
  9. 9.
    Younan R, Kusamura S, Baratti D, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Deraco M. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2005; 12(11):910–918PubMedCrossRefGoogle Scholar
  10. 10.
    Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006; 106(5):1144–1153PubMedCrossRefGoogle Scholar
  11. 11.
    Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49–58Google Scholar
  12. 12.
    Fujimoto S, Takahashi M, Kobayashi K, Kure M, Masaoka H, Ohkubo H, Isaka S, Shimazaki J. Combined treatment of pelvic exenterative surgery and intra-operative pelvic hyperthermochemotherapy for locally advanced rectosigmoid cancer: report of a case. Surg Today 1993; 23:1094–1098PubMedCrossRefGoogle Scholar
  13. 13.
    Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002; 94:492–499PubMedCrossRefGoogle Scholar
  14. 14.
    Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, Steves MA, Sugarbaker PH. Analysis of morbidity and mortality in 60 patients with peritoneal. carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996; 77:2622–2629PubMedCrossRefGoogle Scholar
  15. 15.
    Schnake KJ, Sugarbaker PH, Yoo D. Neutropenia following perioperative intraperitoneal chemotherapy. Tumori 1999; 85(1):41–46PubMedGoogle Scholar
  16. 16.
    Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61–67PubMedCrossRefGoogle Scholar
  17. 17.
    Richard Sylvester. Planning cancer clinical trials. In: Buyse M E, Staquet Maurice J, Sylvester, Richard J. Cancer Clinical Trials. Methods and practice. First Edition. New York: Oxford University Press,1983:48–63Google Scholar
  18. 18.
    Fujimoto S, Takahashi M, Kobayashi K, Kure M, Masaoka H, Ohkubo H, Isaka S, Shimazaki J. Combined treatment of pelvic exenterative surgery and intra-operative pelvic hyperthermochemotherapy for locally advanced rectosigmoid cancer: report of a case. Surg Today 1993; 23(12):1094–1098PubMedCrossRefGoogle Scholar
  19. 19.
    Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, Kusamura S. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11(4):393–398PubMedCrossRefGoogle Scholar
  20. 20.
    Gemba M, Nakatani E, Teramoto M, Nakano S. Effect of cisplatin on calcium uptake by rat kidney cortical mitochondria. Toxicol Lett 1987; 38(3):291–297PubMedCrossRefGoogle Scholar
  21. 21.
    Gordon JA, Gattone VH 2nd. Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 1986; 250(6 Pt 2):F991–998PubMedGoogle Scholar
  22. 22.
    Nechay BR, Neldon SL. Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid. Cancer Treat Rep 1984; 68(9):1135–1141PubMedGoogle Scholar
  23. 23.
    Phelps JS, Gandolfi AJ, Brendel K, Dorr RT. Cisplatin nephrotoxicity: in vitro studies with precision-cut rabbit renal cortical slices. Toxicol Appl Pharmacol 1987 30; 90(3):501–512Google Scholar
  24. 24.
    Miura K, Goldstein RS, Pasino DA, Hook JB. Cisplatin nephrotoxicity: role of filtration and tubular transport of Cisplatin in isolated perfused kidneys. Toxicology 1987; 44(2):147–158PubMedCrossRefGoogle Scholar
  25. 25.
    Fillastre JP, Raguenez-Viotte G. Cisplatin nephrotoxicity. Toxicol Lett 1989; 46(1–3):163–175PubMedCrossRefGoogle Scholar
  26. 26.
    Seguro AC, Shimizu MH, Kudo LH, dos Santos Rocha A. Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am J Nephrol 1989; 9(1):59–65PubMedCrossRefGoogle Scholar
  27. 27.
    Jain S, Seymour AE. Mitomycin C associated haemolytic uremic syndrome. Pathology 1987; 19(1):58–61PubMedGoogle Scholar
  28. 28.
    Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10:863–869PubMedCrossRefGoogle Scholar
  29. 29.
    Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei–a report of 103 procedures. Eur J Surg Oncol 2006; 32(2):186–190. Epub 2005 Nov 21PubMedCrossRefGoogle Scholar
  30. 30.
    Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999; 6:790–796PubMedCrossRefGoogle Scholar
  31. 31.
    Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004; 11:178–186PubMedCrossRefGoogle Scholar
  32. 32.
    Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M. Impact of the extent and duration of cytoreductive surgery on postoperative haematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 2005; 90(4):220–225PubMedCrossRefGoogle Scholar
  33. 33.
    Gianni L, Sessa C, Capri G, Grasselli G, Bianchi G e Vitali G. Farmaci Chemioterapici. In: Bonadona G, Robustelli Della Cuna G, Valagussa P. eds. Medicina Oncologica, 7th edn. Milano: Masson A MediMedia Company, 2003:583–676Google Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Shigeki Kusamura
    • 1
  • Dario Baratti
    • 1
  • Rami Younan
    • 5
  • Barbara Laterza
    • 1
  • Grazia Daniela Oliva
    • 1
  • Pasqualina Costanzo
    • 2
  • Myriam Favaro
    • 2
  • Cecilia Gavazzi
    • 3
  • Federica Grosso
    • 4
  • Marcello Deraco
    • 1
  1. 1.Department of SurgeryNational Cancer Institute of MilanMilanoItaly
  2. 2.Department of Anesthesiology National Cancer Institute of MilanMilanoItaly
  3. 3.Nutritional Care UnitNational Cancer Institute of MilanMilanoItaly
  4. 4.Department of Medical Oncology National Cancer Institute of MilanMilanoItaly
  5. 5.Department of Surgery – Surgical Oncology Unit, CHUMUniversity of Montreal Health CentreMontrealCanada

Personalised recommendations